Organic Active Ingredients TRIZ Cases

Combining EFdA and doravirine uses complementary reverse-transcriptase mechanisms to suppress F227C-mutated HIV and raise the resistance barrier.

This case combines ATP-site anchoring with allosteric interactions in macrocyclic compounds to improve LRRK2 potency and selectivity.

Solvent precipitation creates PDE3/PDE4 inhibitor forms A–C with improved solubility and stability for fixed-dose COPD treatment.

Meta-oriented monomers embed radiopacity in microspheres for embolization imaging without separate contrast agents.

Combining an SGLT-2 inhibitor with an ARB targets blood pressure and glucose while limiting drug interactions in cardiovascular care.

Novel triazole carboxylic acid compounds block LPA1 receptor activation, addressing limited treatments for pulmonary, hepatic, and renal fibrosis.

Three-hydrocarbon-group ammonium lipids help form smaller, stable particles for more efficient nucleic acid delivery to tumors.

Acquired resistance and relapse motivate cyclopropyl-amide compounds that inhibit LSD1 and HDAC together for synergistic cancer growth inhibition.

Specific A1AT dosing before and after hematopoietic cell transplantation targets aGVHD while limiting graft impact from immunosuppression.

Conventional anti-inflammatory treatments may suppress inflammation without treating fibrogenesis; PGAM–CHK1 inhibition modulates glycolytic metabolism.

See how staged contraindication and risk-factor filters qualify subjects for OTC statins before dispensing.

A water-free lipid phase and surfactants address poor intestinal absorption while helping protect peptides and proteins from gastrointestinal instability.

Marine polysaccharide vectors protect anthocyanins from digestive conditions while supporting controlled, fluorescently traceable delivery to the colon.

A pulsed electromagnetic field from a plasma discharge tube sensitizes glioblastoma cells before TMZ, improving efficacy without thermal damage.

Swallowing difficulties call for liquid dosing; hydrocolloids, buffers, and thickeners stabilize metronidazole and baclofen suspensions.

Metal-binding groups coordinate CYP11B2 heme iron to reduce aldosterone synthesis while limiting CYP11B1 inhibition and toxicity.

Specific biaryl structures target DGAT2 to reduce triglyceride synthesis while improving liver selectivity and drug exposure.

Dihydroberberine helps interrupt the Maillard reaction by controlling glucose, scavenging ROS, and reducing MDA and MMP-1 linked to skin aging.

This dairy teat dip pairs iodine with chlorhexidine to address limited efficacy and irritation while extending antimicrobial protection against microorganisms.

This case uses NuRD and CAF-1 complexes to repress DUX4, targeting the mis-expression that drives FSHD muscle weakness.

Mutagenized Bacillus subtilis natto fermentation raises MK-7 output to 200–300 mg/L in 16–24 hours while avoiding chemical synthesis.

A 2-oxapregnane compound targets urination disorders regardless of prostate enlargement, supporting effective prolonged treatment.

A specific E4/DRSP formulation maintains contraceptive efficacy while reducing QT prolongation, C-reactive protein elevation, and free testosterone loss.

For diabetic cataract, midodrine targets aldose reductase and hexokinase pathways to preserve lens transparency and support accurate fundus exams.

Dose-adjusted ubrogepant regimens address migraine treatment when hepatic or renal impairment raises accumulation and adverse-effect risks.

BRD4 inhibitors use an acylaminopyrrolo-pyridone core and varied substituents to improve bromodomain selectivity and ADME properties.

Compound A uses an optimized indole structure and ITK inhibition to prolong remission and suppress multiple sclerosis recurrence and progression.

Plinabulin supports neutrophil survival during docetaxel treatment, reducing neutropenia while preserving chemotherapy effectiveness.

Phase-based oral palovarotene dosing uses lower quiescent-period maintenance and higher flare-up dosing to reduce heterotopic ossification.

See how lipophilic cationic moieties linked to antioxidants accumulate in mitochondria to scavenge ROS and address oxidative stress.

Selective sensitivity of leukemia and myeloma cells to WNK1 inhibitors supports cancer targeting while limiting effects on normal cells.

Antioxidants stabilize sodium picosulfate in a ready-to-use liquid with magnesium citrate, supporting complete dosing without stirring.

Genetic markers, plasma sST2 levels, and polygenic scoring support earlier Alzheimer’s risk assessment before symptoms advance.

This case uses varied compound structures and cleavable prodrug forms to inhibit androgen- and estrogen-receptor-dependent proliferation.

Ataluren promotes ribosomal readthrough in children aged 2–5 to restore dystrophin and delay nmDMD progression.

Macrocyclic compounds recruit CypA to block RAF binding to RAS(ON), extending inhibition beyond KRASG12C to other RAS mutants.

Mitochondrial compounds quench ROS, preserve membrane potential, and increase frataxin levels to support cytoprotection in mitochondrial disorders.

TRPV6-binding peptides pair cancer-cell recognition with fluorescent labels or therapeutic agents for targeted detection and delivery.

Formula I compounds selectively inhibit PRMT5 to regulate histone methylation, reverse gene silencing, and support gamma-globin reactivation.

Variable LNP size and encapsulation can undermine potency; controlled lipid-to-nucleic-acid mixing and pH adjustment target more consistent manufacturing.

Limited oral absorption challenges αvβ6 therapy; these small molecules tune structure to combine target potency with permeability.

C-20 oxime ester modification improves aqueous solubility, enabling rapid intramuscular delivery while supporting stable progesterone release.

Altering the MuSK Ig3 domain can reduce BMP interaction and increase neurogenesis for potential neurodegeneration treatment.

Conventional hydrogels can break in load-bearing joints; functionalized HA and telechelic crosslinkers add elasticity for controlled drug release.

A CD44–Notch–HIF-3α4 fusion gene combines three cancer-suppressive functions in one nucleic acid for viral-vector delivery.

JPH203 selectively inhibits LAT1 over LAT2 to target tumor cells while limiting effects on normal cells in cancer therapy.

Crushing and extraction risks are addressed with polymer-matrix tablets compressed above 40 MPa to keep porosity below 10%.

Substituted piperazine compounds activate or partially activate MC4R orally to suppress food intake and limit cardiovascular side effects.

Proteomic profiling of blood-derived samples classifies patients by predicted TIL benefit, improving selection for personalized cancer treatment.

By depleting glutathione and raising ROS, APR-246 induces ferroptosis in NOTCH1-driven T-ALL despite TP53 status.

This case uses topical lopinavir–ritonavir to inhibit HPV progression and treat cervical dysplasia with less invasive care.

This case uses selected 5' and 3' UTR sequences to stabilize mRNA, promote protein expression, and support efficient antigen synthesis.

Histidine-containing ICG compositions limit aggregation and degradation, preserving fluorescence and enabling extended ambient storage.

This case uses locally modified GalNAc structures and solid-phase conjugation to improve hepatocyte delivery and gene inhibition.

This case combines meloxicam with cyclodextrin and bicarbonate to improve bioavailability and support faster migraine pain relief.

This case combines a fermented and decocted multivitamin with antiretroviral therapy to support nutrition, immunity, and adherence.

This case uses staged SELEX and membrane-bound ICAM-1 selection to improve aptamer specificity before testing rhinovirus inhibition.

This case uses electronegative aryl substituents to improve oral bioavailability and target nAChRs in drug-resistant epilepsy.

Heterocyclic amides inhibit Polθ to sensitize repair-defective cancer cells.

This case develops amino acid compounds that inhibit αvβ6 integrin to treat or delay fibrosis across pulmonary and other tissues.

This case uses fed oral dosing to increase Compound A absorption, exposure, and therapeutic potential for seizure disorders.

This case combines THC, CBD, and minor cannabinoids to modulate sensitization biomarkers and reduce CIPN and SFN pain.

PRN1008 uses reversible BTK inhibition to stabilize platelet counts in ITP.

Roller compaction improves flow and uniformity in bile acid–phenylbutyrate granules.

This case uses piperazino ring derivatives to target PARP1 selectively, sparing PARP2 and limiting hematological side effects.

Peptide conjugates combine melanin binding, cell penetration, and gel formation to sustain drug release on ocular surfaces.

Targeting low bioavailability, these derivatives improve gastrointestinal absorption and stability.

This case uses CNS-affine lipids on oligonucleotides to improve RNAi delivery to neurons, astrocytes, and microglia.

Nme1Cas9, truncated sgRNA, and AAV vectors address off-target effects while enabling precise in vivo genome editing.

This case examines covalent EGFR inhibitors that target Cys775 when C797S limits conventional EGFR drugs.

A phosphate-containing prodrug delivers a dual MDM2/MDMX inhibitor, supporting p53 activation with improved solubility and bioavailability.

A 4–60 mg daily oral LMTX dose reduces methaemoglobin and improves oxygen saturation while avoiding dose-related hypoxia concerns.

Surfactant-based ivermectin compositions improve bioavailability for pain treatment while limiting behavioral and respiratory side effects.

Cell-permeable PARG inhibitors disrupt DNA repair in PARP-resistant cancer cells.

This case shows how pemafibrate activates PPARα and TFEB to address fibrosis, senescence, and lung tissue destruction in COPD and IPF.

Arylene or heteroarylene linkers connect binding agents with maytansinoids for selective delivery and improved treatment efficacy.

This case combines PLK1 inhibition with anti-angiogenic therapy to improve tumor regression and survival in metastatic cancer.

This case combines naltrexone and risperidone to prevent cannabis relapse while alleviating anxiety, depression, and hallucinations.

This case uses modified mRNA and lipid nanoparticles to express FANC proteins while limiting unwanted immune activation.

Molecular substituent changes improve orexin-2 agonist activity, pharmacokinetics, brain permeability, and safety for narcolepsy treatment.

A mutated anti-MUC1 antibody removes Asn57 glycosylation to improve binding affinity and enhance efficacy against MUC1-positive tumors.

This case balances ExPEC serotype coverage by increasing O75 polysaccharide concentration within a carrier-protein vaccine composition.

Formula I compounds target glucocorticoid and mineralocorticoid receptors, reducing liver fat droplets and triglycerides.

Enteric-coated, layered viloxazine formulations combine delayed and extended release to sustain therapeutic levels for up to 24 hours.

This case uses modified SYF2 ASOs delivered intracerebroventricularly or intrathecally to address ALS and FTD treatment gaps.

This composition uses mono-rhamnolipids to disperse ceramides in water-based cosmetics, supporting deposition and skin barrier protection.

This case uses oral 20-hydroxyecdysone compositions to limit strength loss during immobilization without affecting muscle mass.

Protease degradation and water-saturated 1-butanol extraction produce a nerve growth promoter.

Carrageenan forms the aqueous gel network while ethylcellulose retards skin migration for controlled topical release.

This case combines phosphatidylcholine with GCA or TCA to reduce localized fat and support shorter dosing intervals with fewer side effects.

This case pairs intravenous mitoxantrone liposome with oral capecitabine to improve response and survival in recurrent disease.

This case combines lomitapide with chemotherapy or anti-PD1 therapy to suppress colorectal cancer growth and induce cell death.

A mutated Fc region targets a CDN-based STING agonist to antigen-expressing tumors while balancing effector activity and safety.

Administering OBE001 in the luteal phase reduces uterine contractions and supports embryo implantation in ART.

A multi-excipient apixaban formulation disintegrates in under 3 minutes, supporting consistent absorption without water.

Modified siRNAs target PRDX5 and GPX4 alongside enzalutamide to suppress CRPC growth and reduce tumor size.

Modified oligonucleotides trigger RNase H cleavage of ATXN3 mRNA, reducing Ataxin-3 protein and toxic aggregate formation in SCA3.

This case uses Ganoderma tRF-31 RNA and delivery carriers to curb airway remodeling, inflammation, and abnormal smooth muscle growth.

This case uses topical aggrelytes to acetylate lens proteins, reduce disulfide bonds, and restore lens flexibility for presbyopia.

This case uses localized substituents and stereochemistry to improve FGFR2 selectivity while maintaining inhibition activity.

Enteric coated microcapsules protect mTOR inhibitors from stomach acid, ensuring stable intestinal release to delay aging and treat age-related diseases.

Phenyl substituted cyclohexenyl compounds reduce body weight without triggering the psychiatric side effects associated with traditional cannabinoid therapies.

3-Ethynylpyrazolopyrimidine derivatives inhibit SRC, Abl, and RET kinases.

Composite hemostatic bandage prevents severe blood flow while allowing easy removal without damaging newly formed tissue.

Mold casting creates apertures in a bioresorbable polymer film, avoiding mechanical perforation damage while ensuring complete drug delivery.

Chromatographic separation isolates a specific sulfated heptasaccharide from low molecular weight heparin mixtures.

Allosteric compounds bind to a specific regulatory subdomain of ALK2 kinase, reducing off-target inhibition.

Inhibiting GDF6 activity overcomes BRAF inhibitor drug resistance by reducing melanoma cell proliferation.

Formula Ia cannabinoid receptor modulators resolve the trade-off between treatment efficacy and cancer type specificity by targeting distinct indications.

Novel bifunctional compounds induce irreparable DNA lesions in cancer cells, overcoming temozolomide resistance in MGMT-deficient tumors.

Co-administering bupropion with dextromethorphan inhibits hepatic metabolism, resolving rapid clearance limitations in extensive metabolizers.

Resistant potato starch modulates the gut microbiome to increase beneficial bacteria and reduce harmful pathogens without complex probiotic formulations.

Amiselimod employs a two-phase dosing regimen to resolve the contradiction between treatment efficacy and safety limitations in ulcerative colitis.

Enhancing efferocytosis via CD47-SIRPα modulation clears necrotic core debris, reducing plaque vulnerability and rupture risk.

Specific substituent patterns on the pyrimidine core achieve selective class Ia inhibition, reducing off-target effects from non-selective inhibitors.

A hyaluronic acid and flavonoid particle suspension retains bioactive agents via non-covalent bonds for cellular delivery.

Oxidative crosslinking of ferulic acid moieties enables low sugar hydrogels that maintain structural integrity at pH 1.5-2.5.

A pharmaceutical combination of a CCR1 receptor antagonist and a glucocorticosteroid reduces inflammatory cell influx in the lungs.

A pharmaceutical kit containing quick-release and slow-release melatonin doses tailored to specific circadian shifting needs.

MTA-cooperative small molecule inhibitors target PRMT5 in cancer cells through elevated MTA accumulation.

A sensor array detects volatile organic compounds in the ear canal to identify neurological disease signatures.

DANA and AMPCA formulations decrease alveolar wall thickness and lower serum cytokine levels to treat COVID-19-associated lung damage.

Segmented synthesis resolves yield-purity contradictions in diarylthiohydantoin production by optimizing amide-bond formation and phosgene treatment steps.

Combining iguratimod with methotrexate creates a pharmaceutical composition that treats autoimmune diseases.

Inhaled delivery of novel compounds concentrates antifungal agents at the lung airway, bypassing systemic toxicity while treating resistant mycoses.

A thermoresponsive hydrogel polymer system injects as a liquid and gels at body temperature to form a 3D scaffold.

Amide-substituted heterocyclic compounds inhibit Tyk2 kinase activity to modulate cytokine signaling pathways.

Substituted imidazo[1,2-b]pyridazine compounds selectively inhibit Akt kinases to resolve unspecific targeting of the Pi3K/Akt pathway in cancer therapy.

A fused heterocyclic compound derivative modulates dopamine and serotonin receptors to treat neuropsychiatric disorders.

Hyaluronan-tocopherol conjugates deliver these agonists to skin cancer sites, reducing systemic side effects while maintaining local efficacy.

Modifying the chemical structure of carbenoxolone eliminates mineralocorticoid side effects while preserving gap junction inhibition.

Formula I compounds reduce viral loads and clear RNA, addressing toxicity issues in hepatitis C treatments.

Non-steroidal dibenzo[b,f]pyrido[1,2-d]oxazepine-2-amines reduce cross-reactivity with glucocorticoid receptors to minimize side effects.

Combining anti-CLDN18.2 antibodies with chemotherapy and PD-1 inhibitors overcomes limited efficacy in CLDN18.2-expressing cancers.

Irreversible binding of dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives to mGluR2 receptors resolves variable clinical efficacy and specificity limitations.

Biodegradable polymer microspheres deliver therapeutic agents to joint fat pads.

Replacing polyphosphorhydrazone linkages with thiophosphoramidate units prevents hydrolysis at physiological pH, ensuring stability for biological applications.

Competitive inhibitors displace radionuclides from healthy organs to reduce radiation exposure while maintaining tumor targeting.

Engineered antibodies target STn and Neu5Gc antigens to reduce tumor volume while avoiding off-target effects.

Atrial electrogram analysis identifies reactive oxygen species-associated cardiac tissue through signal correlation patterns.

Cinnamic hydroxymate compounds selectively inhibit Class IIa histone deacetylases through precise molecular binding.

1,4,8-Triazaphenanthrene derivatives cross the blood-brain barrier to halt neurodegenerative disease progression beyond symptomatic relief.

A synergistic composition of L-ergothioneine and nicotinamide mononucleotide improves cellular health.

Grafting lignin onto PLGA eliminates surfactant removal steps while enabling stable nanoparticle formation for effective cancer treatment.

Pyrazine and pyridine compounds inhibit ATR kinase, disrupting DNA repair processes to enhance treatment effectiveness against cancer cells.